These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33449413)

  • 1. Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D-/R-).
    Jorgenson MR; Descourouez JL; Yang DY; Stalter LN; Leverson GE; Parajuli S; Mandelbrot DA; Smith JA; Redfield RR
    Transpl Infect Dis; 2021 Jun; 23(3):e13564. PubMed ID: 33449413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation.
    Belga S; MacDonald C; Chiang D; Kabbani D; Shojai S; Abraldes JG; Cervera C
    Clin Infect Dis; 2021 Mar; 72(5):845-852. PubMed ID: 32025704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
    Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients.
    Vutien P; Perkins J; Biggins SW; Reyes J; Imlay H; Limaye AP
    Liver Transpl; 2021 Sep; 27(9):1302-1311. PubMed ID: 33687777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States.
    Geris JM; Spector LG; Pfeiffer RM; Limaye AP; Yu KJ; Engels EA
    Cancer; 2022 Nov; 128(22):3985-3994. PubMed ID: 36126024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
    da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
    Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB; Pouch SM; Phadke VK; Karadkhele G; Larsen CP; Woodworth MH
    Transpl Infect Dis; 2024 Feb; 26(1):e14219. PubMed ID: 38158932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors.
    Belga S; Hussain S; Avery RK; Nauroz Z; Durand CM; King EA; Massie A; Segev DL; Connor AE; Bush EL; Levy RD; Shah P; Werbel WA
    J Heart Lung Transplant; 2024 Apr; 43(4):615-625. PubMed ID: 38061469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients.
    Forlanini F; Dara J; Dvorak CC; Cowan MJ; Puck JM; Dorsey MJ
    Transpl Infect Dis; 2021 Apr; 23(2):e13504. PubMed ID: 33169931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
    Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
    Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
    Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
    Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
    Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.